Aurobindo Pharma gets FTC nod for $250m Lannett buy

FTC clearance removes a key closing hurdle

Aurobindo Pharma Ltd said its wholly owned subsidiary, Aurobindo Pharma USA Inc., has received approval from the US Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. The approval is a key milestone because it clears the main antitrust review needed to complete the transaction. The company disclosed the development through regulatory filings to Indian stock exchanges. Aurobindo indicated it expects the deal to close before the end of June 2026, subject to customary closing procedures. Reports referenced in the disclosures also described the clearance as coming with conditions. The update brought the stock into focus in early trade.

Deal structure: acquisition of 100% membership interest

Aurobindo Pharma USA Inc. is buying a 100% membership interest in Lannett Company LLC. The seller entity named in disclosures is LANNETT SELLER HOLDCO, INC. Aurobindo said the transaction is on a cash-free, debt-free basis and includes normalized working capital. The company has also stated that the transaction is expected to be immediately accretive to the Aurobindo Group’s earnings per share. The FTC approval was disclosed as having been received on June 19, 2026, in one regulatory update. Reuters also reported on June 18, 2026 that the FTC announced a divestiture requirement tied to the deal. With the antitrust step completed, the company said it expects to finish remaining formalities and close within the month.

Valuation: $150 million reported, with some variance

Aurobindo has been widely reported as pursuing the acquisition in a deal valued at $150 million (also cited as approximately ₹2,365 crore in one disclosure). Another market snapshot cited $150 million as approximately ₹2,090 crore, reflecting variability in approximate conversions used by different reports. Separately, some reports referenced the transaction size at around $150 million. Aurobindo’s filings referenced the FTC approval and the expected closing timeline, while market coverage carried differing numbers on deal value. The consistent thread across disclosures is that the acquisition is near completion after the FTC green light. The company has said it will keep stock exchanges informed if there are future developments.

What the FTC conditions require

According to reports, the FTC cleared the acquisition through a consent order with conditions attached. The condition cited is that Aurobindo must divest four generic drug products to Quagen Pharmaceuticals LLC, a New Jersey-based generics maker. Reuters reported that the FTC’s concern was that the transaction would combine two of a limited number of competitors across markets for four generic pharmaceutical products. The FTC was quoted by Reuters as saying these drugs provide critical relief for patients, ranging from medicines used to prevent organ transplant rejection to tablets that treat dry mouth after radiation therapy. The divestiture requirement is aimed at addressing potential anticompetitive outcomes. Aurobindo’s transaction, as described in the reports, proceeds with this divestment obligation.

Why Lannett matters to Aurobindo’s US strategy

Lannett is a Pennsylvania-based generic pharmaceutical company focused on the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances. Aurobindo said the acquisition will enhance its portfolio with a differentiated pipeline of complex generics and controlled substances. The company also flagged expected cost efficiencies, SG&A synergies, and operational integration advantages. From Aurobindo’s perspective, the combination expands Aurobindo USA’s product offering in complex generics and controlled substances. It also adds a US-based manufacturing facility to Aurobindo’s network. The stated intent is to support sustainable long-term growth through portfolio and footprint expansion.

Manufacturing footprint: Seymour, Indiana capacity added

Aurobindo said Lannett’s manufacturing site in Seymour, Indiana will become part of its US manufacturing network after the acquisition closes. The facility has capacity to scale production to approximately 4 billion doses annually. A market snapshot also referenced an expansion to include a 425,000 sq. ft. facility, describing it as part of the broader US manufacturing footprint. Taken together, the transaction adds meaningful domestic manufacturing capability in the US. For Aurobindo USA, this strengthens its ability to supply complex generic products from within the country. The company positioned the integration as bringing operational advantages alongside capacity.

Timeline: from agreement in 2025 to closing in June 2026

Aurobindo Pharma USA Inc. entered into a definitive agreement in July 2025 to acquire Lannett Company LLC from LANNETT SELLER HOLDCO, INC. The FTC approval was disclosed as being received on June 19, 2026. Reuters separately carried an FTC announcement dated June 18, 2026 on the divestiture condition. The company has repeatedly stated that the deal is expected to close before the end of June 2026, subject to remaining formalities. This places closing roughly a year after the definitive agreement was announced. The regulatory clearance is framed by the company as the major hurdle removed before completion.

Market reaction: shares rise in early trade

After the regulatory update, Aurobindo Pharma shares saw a positive early reaction in the market. One report said the stock gained over 1.7% in early trading following the announcement. Another report said the stock rose as much as 1.53% to ₹1,465.80 on the NSE in early trade. A separate market update said the stock gained about 2% to ₹1,472, while at 11:30 AM it was up 1.7% at ₹1,467, with around 1 lakh shares traded versus a two-week average of around 34,000 shares on the BSE. These data points indicate the stock was in focus and moved higher even as broader market conditions were described as negative in one update. The moves reflect investor attention to regulatory certainty and deal closure visibility.

Key facts at a glance

Market impact: what changes once the deal closes

The immediate market impact described in reports was a rise in Aurobindo Pharma’s share price after the FTC approval became public. Operationally, the acquisition adds a US-based manufacturing facility and meaningful production capacity in Seymour, Indiana, which can scale to around 4 billion doses annually. On the portfolio side, Aurobindo said the deal strengthens its offering in complex generics and non-opioid controlled substances. The FTC condition requiring divestment of four generic products to Quagen Pharmaceuticals is a material element, because it shapes which products remain with the combined entity post-closing. The company has also said the acquisition should be immediately accretive to earnings per share, a point that tends to matter for near-term investor expectations. Beyond the transaction itself, the disclosures also referenced management aiming for a US revenue milestone of $1,000 million (that is, $1 billion), positioning this acquisition within a broader US scaling plan.

Analysis: why this FTC decision matters

FTC clearance matters because it reduces uncertainty around whether the acquisition can proceed on the planned timeline. The divestiture requirement underscores that antitrust scrutiny was focused on overlap in specific generic markets, and the remedy is designed to preserve competition by transferring products to another manufacturer. For Aurobindo, the strategic rationale described is a mix of portfolio enhancement and operational integration, including cost efficiencies and SG&A synergies. The manufacturing element is also central: adding a US facility and high dose capacity supports the company’s stated goal of strengthening its domestic manufacturing footprint. The market response reported, with the stock rising around 1.5% to 2% in early trade, suggests investors reacted to the clarity provided by the regulatory milestone. However, the presence of different reported deal values ($150 million versus around $150 million) is a reminder that readers should anchor to company filings for definitive transaction terms.

Conclusion: closing expected by end-June 2026

Aurobindo Pharma has confirmed that its US subsidiary received FTC approval to proceed with the Lannett acquisition, a key step toward closing the deal. The transaction is expected to be completed before the end of June 2026, subject to customary closing procedures. Reports indicate the FTC approval includes a condition to divest four generic drug products to Quagen Pharmaceuticals. Once completed, the acquisition adds Lannett’s complex generics and controlled substances portfolio and brings a US manufacturing site in Seymour, Indiana with capacity to scale to about 4 billion doses annually. Aurobindo said it will keep exchanges informed if there are further developments as the closing process is completed.